Vor Biopharma Stock Performance
| VOR Stock | USD 9.84 8.96 47.66% |
The entity has a beta of -0.11, which indicates not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Vor Biopharma are expected to decrease at a much lower rate. During the bear market, Vor Biopharma is likely to outperform the market. At this point, Vor Biopharma has a negative expected return of -1.74%. Please make sure to validate Vor Biopharma's maximum drawdown and rate of daily change , to decide if Vor Biopharma performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Vor Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unsteady performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in December 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
Actual Historical Performance (%)
One Day Return (47.66) | Five Day Return (47.72) | Year To Date Return (56.07) | Ten Year Return (98.69) | All Time Return (98.69) |
Last Split Factor 1:20 | Last Split Date 2025-09-19 |
1 | Disposition of 554612 shares by Reprogrammed Interchange Llc of Vor Biopharma at 1.9961 subject to Rule 16b-3 | 09/03/2025 |
2 | Disposition of 449226 shares by Reprogrammed Interchange Llc of Vor Biopharma at 2.0004 subject to Rule 16b-3 | 09/09/2025 |
3 | Disposition of 350000 shares by Reprogrammed Interchange Llc of Vor Biopharma at 1.8151 subject to Rule 16b-3 | 09/10/2025 |
4 | We Think Vor Biopharma Needs To Drive Business Growth Carefully | 09/11/2025 |
5 | THE WORLDS 50 BEST BARS STELLT DIE LISTE DER BARS VON 51-100 VOR | 09/24/2025 |
6 | Disposition of 5300 shares by Reprogrammed Interchange Llc of Vor Biopharma at 42.319 subject to Rule 16b-3 | 10/02/2025 |
7 | Disposition of 14336 shares by Reprogrammed Interchange Llc of Vor Biopharma at 34.3391 subject to Rule 16b-3 | 10/08/2025 |
8 | Disposition of 15042 shares by Reprogrammed Interchange Llc of Vor Biopharma at 32.4052 subject to Rule 16b-3 | 10/09/2025 |
9 | Disposition of 2334 shares by Reprogrammed Interchange Llc of Vor Biopharma at 33.0873 subject to Rule 16b-3 | 10/13/2025 |
10 | Disposition of tradable shares by Ra Capital Management, L.p. of Vor Biopharma at 31.17 subject to Rule 16b-3 | 10/15/2025 |
11 | Disposition of 11616 shares by Reprogrammed Interchange Llc of Vor Biopharma at 30.0535 subject to Rule 16b-3 | 10/20/2025 |
12 | Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjgrens Disease | 10/22/2025 |
13 | Disposition of 53345 shares by Ra Capital Management, L.p. of Vor Biopharma at 28.01 subject to Rule 16b-3 | 10/24/2025 |
14 | Disposition of 90941 shares by Ra Capital Management, L.p. of Vor Biopharma at 28.12 subject to Rule 16b-3 | 10/27/2025 |
15 | Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data | 10/29/2025 |
16 | Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 10/31/2025 |
17 | Can Vor Biopharma Inc. stock maintain operating margins - Market Weekly Review Weekly High Conviction Ideas - newser.com | 11/06/2025 |
18 | Vor Biopharma Secures 100 Million Offering After Reporting Efficacy In Kidney Disease Trial | 11/11/2025 |
| Begin Period Cash Flow | 33.8 M | |
| Total Cashflows From Investing Activities | 96.9 M |
Vor Biopharma Relative Risk vs. Return Landscape
If you would invest 3,960 in Vor Biopharma on August 14, 2025 and sell it today you would lose (2,976) from holding Vor Biopharma or give up 75.15% of portfolio value over 90 days. Vor Biopharma is generating negative expected returns assuming volatility of 8.6616% on return distribution over 90 days investment horizon. In other words, 77% of stocks are less volatile than Vor, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Vor Biopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Vor Biopharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Vor Biopharma, and traders can use it to determine the average amount a Vor Biopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2005
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | VOR |
Estimated Market Risk
| 8.66 actual daily | 77 77% of assets are less volatile |
Expected Return
| -1.74 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.2 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Vor Biopharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Vor Biopharma by adding Vor Biopharma to a well-diversified portfolio.
Vor Biopharma Fundamentals Growth
Vor Stock prices reflect investors' perceptions of the future prospects and financial health of Vor Biopharma, and Vor Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Vor Stock performance.
| Return On Equity | -1.25 | ||||
| Return On Asset | -1.21 | ||||
| Current Valuation | (71.71 M) | ||||
| Shares Outstanding | 6.85 M | ||||
| Price To Book | 3.14 X | ||||
| EBITDA | (113.39 M) | ||||
| Net Income | (116.91 M) | ||||
| Cash And Equivalents | 151.09 M | ||||
| Cash Per Share | 3.97 X | ||||
| Total Debt | 31.83 M | ||||
| Debt To Equity | 0.24 % | ||||
| Current Ratio | 12.95 X | ||||
| Book Value Per Share | (239.67) X | ||||
| Cash Flow From Operations | (99.66 M) | ||||
| Earnings Per Share | (273.60) X | ||||
| Market Capitalization | 67.44 M | ||||
| Total Asset | 142.89 M | ||||
| Retained Earnings | (456.99 M) | ||||
| Working Capital | 77.89 M | ||||
About Vor Biopharma Performance
Assessing Vor Biopharma's fundamental ratios provides investors with valuable insights into Vor Biopharma's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Vor Biopharma is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.82) | (0.86) | |
| Return On Capital Employed | (0.98) | (1.02) | |
| Return On Assets | (0.82) | (0.86) | |
| Return On Equity | (1.21) | (1.27) |
Things to note about Vor Biopharma performance evaluation
Checking the ongoing alerts about Vor Biopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Vor Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Vor Biopharma generated a negative expected return over the last 90 days | |
| Vor Biopharma has high historical volatility and very poor performance | |
| Vor Biopharma has a very high chance of going through financial distress in the upcoming years | |
| Reported Net Loss for the year was (116.91 M) with profit before taxes, overhead, and interest of 0. | |
| Vor Biopharma has about 151.09 M in cash with (99.66 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.97. | |
| Vor Biopharma has a poor financial position based on the latest SEC disclosures | |
| Roughly 29.0% of the company outstanding shares are owned by insiders | |
| Latest headline from finance.yahoo.com: Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635 |
- Analyzing Vor Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Vor Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining Vor Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Vor Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Vor Biopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Vor Biopharma's stock. These opinions can provide insight into Vor Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Vor Stock Analysis
When running Vor Biopharma's price analysis, check to measure Vor Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vor Biopharma is operating at the current time. Most of Vor Biopharma's value examination focuses on studying past and present price action to predict the probability of Vor Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vor Biopharma's price. Additionally, you may evaluate how the addition of Vor Biopharma to your portfolios can decrease your overall portfolio volatility.